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PIR-B, an inhibitory receptor expressed on murine B cells and myeloid cells, regulates humoral and cellular immune responses
via its constitutive binding to the ligand, MHC class I molecules, on the same cells (cis)o ro nd i ﬀerent cells (trans). Although it
has been speculated that PIR-B is important for maintaining peripheral tolerance, PIR-B single deﬁciency does not cause overt
autoimmune diseases. Recently, however, the combination of its deﬁciency with the Fas lpr mutation was found to result in
augmented production of autoantibodies such as IgG rheumatoid factor and anti-DNA IgG, leading to glomerulonephritis in
mice. Although the precise molecular mechanism for the overall scenario is unclear, PIR-B was found to suppress TLR9-mediated
production of naturally autoreactive antibodies by innate B cells or B-1 cells by inhibiting the activation of Bruton’s tyrosine
kinase. Thus, PIR-B is an important regulator of innate immunity mediated by TLR9 in B-1 cells, which can otherwise provoke
autoimmunity when overactivated.
1.Introduction
B cells are continuous producers of natural antibodies with
potential reactivities to autologous tissues as well as the
on-demand factories of high-aﬃnity antibodies principally
against pathogens. Because various self-reactive antibodies
are produced in many autoimmune diseases through several
elusive mechanisms, a regulatory network for maintaining
tolerance to self in B cells while keeping the potential for
producing antibodies with speciﬁcities and aﬃnities against
foreign antigens in suﬃcient amounts has long been a
challenging ﬁeld for immunologists.
We are now aware of that a series of inhibitory
receptors are expressed preferentially on B cells and other
immunoregulatory cells such as dendritic cells (DCs). Thus,
the roles of these receptors, including that of the paired
immunoglobulin- (Ig-) like receptor (PIR)-B [1, 2] in the
regulation of B cells, which we will describe in detail in
this paper, have been attracting much interest from many
researchers. Some intriguing knowledge on the regulatory
role of PIR-B in the immune system has already been
reported elsewhere [3–5]( Table 1). Therefore, after brieﬂy
overviewing PIR-B’s novel characteristics revealed in the past
several years, this paper will mainly deal with the recent
progress of the understanding of PIR-B-mediated immune
regulation, particularly focusing on its role in controlling
the production of potential autoantibodies in response to
activation via innate-immune stimuli.
2.PIR-BIstheMHCClassIReceptor in
BCells andMyeloidCells
2.1. Recognition of MHC Class I Molecules. In the immune
system, there are three types of major histocompatibility
complexclassI-(MHCI-)recognitionmolecules.Inaddition
to the well-known T cell receptor (TCR)-CD8 complex of
CD8+ T cells and the killer cell receptors on NK cells,
mammalian B cells and myeloid-lineage cells possess the
third type of MHCI-recognizing inhibitory receptors, which
may constitutively regulate these cells. The latter are murine
PIR-B and its close relatives or orthologs in humans, the
leukocyte Ig-like receptors (LILR)B1 and LILRB2 [3, 4, 6, 7].
In contrast to the former two types of receptors, which target
the polymorphic α1/α2 region of MHCI, LILRB molecules
were demonstrated to bind a constant α3d o m a i na n dβ22 Journal of Biomedicine and Biotechnology
microglobulin of MHC [8, 9]. PIR-B’s mode of recognition
of MHCI has not been clariﬁed yet, although it is speculated
to be essentially the same as that of LILRB [4].
2.2. Protein Structure. PIR-B is a type I transmembrane
glycoprotein comprising six extracellular Ig-like domains,
a hydrophobic transmembrane segment, and a cytoplas-
mic portion with four immunoreceptor tyrosine-based
inhibitory motif (ITIM) or ITIM-like sequences (Figure 1).
Comparison of the available sequences of PIR extracellular
portions from 129/Sv, B10.A, and BALB/c mice indicated
fairly high sequence similarity, but multiple substitutions of
amino acid residues were observed like in LILR molecules
[23], especially in the ﬁrst four ectodomains [2, 24]. It is
not known whether these polymorphisms could modulate
the binding of PIR-B to various MHCI and its inhibitory
functions.
2.3. Expression. PIR-B is expressed on B cells and myeloid-
lineagecellsincludingmastcells,macrophages,granulocytes,
DCs, and osteoclasts, but not on thymocytes, mature T
cells, or NK cells [1, 2, 25, 26]. PIR-B expression takes
place mostly in a pairwise fashion with PIR-A, an activating
isoform associated with the Fc receptor common γ subunit
(FcRγ), as judged on Western blot analysis [25]. In many
cases, however, the cell-surface expression of PIR-B occurs
more predominantly than that of PIR-A, as judged on ﬂow
cytometric analysis of PIR-B- or FcRγ-deﬁcient cells with
a speciﬁc monoclonal antibody (mAb), 6C1, that targets a
shared epitope of PIR-B and PIR-A [10, 14, 25]. In mature
naive B cells, PIR-B is exclusive on the surface [10]. The cell
surface levels of PIR molecules on myeloid- and B-lineage
cellsincreasewithcellulardiﬀerentiationandactivation[25].
ThePIR-Blevelishighestonmarginalzone(MZ)Bcells,and
B-1 cells express higher PIR-B levels than B-2 cells [11, 25].
2.4. Unexpected Role in the Neuronal System. Recently, it was
reportedthatPIR-Bandoneofitshumanorthologs,LILRB2,
are expressed on neuronal cells [20, 21]. In addition, Atwal
et al. [21] have identiﬁed three proteins expressed in the
central nervous system as the novel physiological ligands for
PIR-B and LILRB1. These are neurite outgrowth inhibitor
protein (Nogo)A, myelin-associated glycoprotein (MAG or
Siglec-4), and oligodendrocyte myelin glycoprotein (OMgp)
[21]. This ﬁnding suggests a novel notion that PIR-B is not
only a receptor of MHCI for immune regulation but also
a determinant of neuronal regeneration responding to the
multiple ligands in the central nervous system. These issues
have recently been reviewed extensively elsewhere [27, 28].
3. SignalRegulation by PIR-B
3.1. Cis/Trans Binding to MHCI. Considering the ubiquitous
expression of MHCI molecules on hematopoietic as well as
nonhematopoietic cells, the question arises as to whether
PIR-B can recognize MHCI on the same cells (in cis), on
diﬀerent cells (in trans), or both. It has been shown that
inhibitory Ly49A expressed on murine NK cells not only
binds to its H-2Dd ligand expressed on the potential target
cells in trans but also is constitutively associated with H-
2Dd in cis [29]. The cis association and trans interaction
occur through the same binding site. Consequently, the cis
association restricts the number of Ly49A receptors available
for the trans binding of H-2Dd on target cells and reduces
NKcellinhibitionbyloweringthethresholdatwhichNKcell
activation exceeds NK cell inhibition [30–32]. This notion,
however, has not been veriﬁed to be the rule for every
inhibitory receptor that binds to its physiological ligand
expressed in the own tissues.
OurstudyonmastcellregulationbyPIR-Binthecontext
of allergic responses in Pirb
−/− mice veriﬁed that PIR-B
on mast cells binds to MHCI molecules in cis,a sj u d g e d
on ﬂuorescence resonance energy transfer (FRET) analysis
[14]. In addition, FRET revealed that the cis interaction
was also the case for the interaction between MHCI and
LILRB2 expressed on human basophilic leukemia KU812
cells. Interestingly, mast cell responses to stimulation by
IgE crosslinking or lipopolysaccharides were suppressed to
a signiﬁcant extent by such a cis interaction on the mast
cell surface. In both PIR-B and β2-microglobulin, its ligand,
deﬁciency, both the in vitro cytokine responses and in
vivo anaphylactic responses were signiﬁcantly augmented,
suggestingthephysiologicalimportance ofthe cisinteraction
[14]. Our analysis of osteoclast precursor cells revealed that
the development of osteoclasts is also regulated by PIR-B and
that this regulatory mechanism involves the cis interaction
of PIR-B-MHCI on osteoclast precursor cells [26]. The cis
interaction between PIR-B and MHCI was found also on
other cell surfaces such as that of B cells and DCs [13].
PIR-B on DCs and MHCI on CD8+ Tc e l l sw e r e
found to interact in trans at the immunological synapse.
Moreover, CD8+ Tc e l l sw e r ef o u n dt ob em o r ea c t i v a t e d
upon interaction with Pirb
−/− DCs than wild-type cells.
This observation was unexpected, because it was known
that Pirb
−/− DCs could not support suﬃcient CD4+ Tc e l l
activation toward Th1 development due to their insuﬃcient
maturation in PIR-B deﬁciency and reduced secretion of IL-
12 [10]. Considering the possibility that MHCI molecules
on DCs could play a role as a shared ligand for CD8 on
T cells and for PIR-B on the DCs themselves, it would be
interesting to test the hypothesis that CD8 and PIR-B could
be competitive as to binding to MHCI on DCs, and it was
demonstrated that this was the case [13]. Surface plasmon
resonance analysis revealed that PIR-B and CD8αα compete
in binding to MHCI. In vitro and in vivo analyses also
veriﬁed that Pirb
−/− DC provoked cytotoxic T lymphocytes
(CTLs) more eﬃciently, leading to accelerated rejection of
skin grafts and tumors. Thus, PIR-B regulates CTL triggering
byblockingtheaccessofCD8moleculestoMHCI.Itremains
to be determined whether or not PIR-B on DCs is more
prone to bind MHCI in trans on CD8+ T cells than the
binding in cis when an immunological synapse is induced
between DC-CD8+ T cells.
3.2. Immune Regulation. Studies on Pirb
−/− mice during
the past 10 years have provided us with an insight intoJournal of Biomedicine and Biotechnology 3
Table 1: Phenotypes observed in Pirb
−/− mice and Pirb transgenic (tg) mice.
Mice Cellsa Phenotypesb References
Pirb−/−
B-2 cells Enhanced proliferation upon BCR
stimulation
[10]
B-1 cells Enhanced proliferation and autoantibody
production upon CpG stimulation
[11]
DCs Impaired maturation [10]
Exacerbated graft-versus-host disease [12]
CD8+ Tc e l l s Augmented activation [13]
Mast cells Augmented anaphylaxis [14]
Macrophages Augmented cytokine and chemokine
signaling
[15]
Neutrophils Augmented integrin signaling [16]
Eosinophils Enhanced recruitment in Th2 response [17]
Macrophagesc Sensitive to Salmonella infection [18]
Macrophages Reduced binding of Staphylococcus aureus [19]
Neuronal cells Enhanced plasticity of visual nerve
connections
[20]
Enhanced neurite outgrowth [21]
Pirb tg Thymocytes Normal development [22]
Mature T cells Impaired Th1 response [22]
aCells involved mainly in the observed phenotype.
bMajor phenotypes observed.
cUnidentiﬁed, though involving macrophages.
Autoimmunity
Auto-reactive
IgM-RF, IgG-RF
Bacterial/viral
CpG DNA
MHC class I/β2m PIR-B
SHP-1
Lyn
Btk
TLR9
MyD88
IRAK
TRAF6
IκB
NF-κB
p50/p65
NF-κB Inﬂammatory
cytokines, Igs
Plasma membrane
Nuclearm e m b r a ne
Endosome
P
P P
P
Figure 1: Proposed mechanism for PIR-B-mediated regulation of TLR9-induced autoantibody production in B-1 cells. Unmethylated
CpG-harboring DNA of bacterial and viral origin stimulates TLR9 in the endosomal compartments of various cells including B-1 cells
via signal relay from MyD88, IRAK, and TRAF6, and then IκB phosphorylation, nuclear translocation of NF-κB, and initiation of the
transcription of various mRNAs of innate responses, including those for autoreactive natural antibodies. Excess activation of the TLR9
system is thus potentially harmful, because excessive production of autoreactive IgM and, particularly, that switched to IgG might cause
autoimmune disease. TLR9 in B-1 cells is regulated by PIR-B via Btk intersection, in which the phosphorylation of PIR-B is augmented
immediately through TLR9-initiated Lyn activation, and the concomitantly enhanced SHP-1 recruitment to the phospho-ITIMs of PIR-B
leads to accelerated dephosphorylation of Btk, which then attenuates the phosphorylation level of NF-κB p65RelA. Constitutive association
of PIR-B with MHCI in cis on the surface of B-1 cells may be crucial for maintaining the TLR9 cascade being not overactivated, and once
activated by CpG, immediate early suppression will occur via augmented SHP-1 recruitment to PIR-B-MHCI.4 Journal of Biomedicine and Biotechnology
the physiological signiﬁcance of the MHCI recognition
by PIR-B in the immune responses, especially in B cell
activation, antigen presentation, humoral immunity, and
transplantation (Table 1), most of which have already been
described elsewhere [3–5]. This section deals with the recent
ﬁndings on the PIR-B’s functions in bacterial infection,
eosinophil signaling, and T cell functions brieﬂy, and in the
next section we will focus on its roles in autoimmunity.
3.2.1. Eosinophil Function. Munitz et al. [17]d e s c r i b e da
positive and negative dual regulatory role of PIR-B in Th2
inﬂammation, in which PIR-B shows overexpression on
eosinophils. Based on the diﬀerent responses to eotaxin- or
leukotrieneB4-dependentchemotaxisofPirb
−/− eosinophils,
it was found that extracellular signal-related kinase 1 and 2
or Erk1/2 phosphorylation in response to these stimulators
was opposite in eosinophils in vitro. It was proposed that an
inhibitory receptor can exhibit dual functionality in distinct
cell types after unique cellular signals [17]. This interesting
hypothesis will have to be evaluated in other cellular and
experimental settings as well as in other receptor systems,
which might shift our idea of merely “inhibitory” receptors
to more sophisticated “regulatory” ones.
3.2.2. T Cell Development and Function. PIR-B is expressed
on immature and mature B cells, and myeloid cells but not
on NK cells or T cells. However, besides the speculation
that PIR-B should be under the control of B/myeloid-speciﬁc
transcription factors, it has been unknown why T cells and
NK cells preferentially use inhibitory coreceptors such as
CTLA-4, PD-1, and KIRs, but not PIR-B. This issue should
be considered how PIR-B expression is regulated during
prethymic progenitor cells, thymocytes, and mature T cells,
referring functional consequences when PIR-B is genetically
deleted or expressed by force.
Masuda et al. [33] serendipitously found that PIR
immunoreactivity was transiently detected on very early
prethymic progenitors of T/NK/DCs, although PIR is not
f o u n do nt h y m o c y t e so rm a t u r eTc e l l so nﬂ o wc y t o m e t r y
and immunohistochemistry with mAb 6C1 recognizing both
PIR-A and PIR-B [25]. PIR expression was maintained until
the earliest intrathymic stage and then downregulated before
the onset of CD25 expression, which is a hallmark of the
earliest stage of double negative thymocytes [33], suggesting
that PIR-B expression should be down modulated during
thymic development. Then, for what is it suppressed? The
above ﬁndings prompted us ﬁrstly to deﬁne in more detail
the cells at prethymic and intrathymic stages of T cell
development in PIR-B deﬁciency. We found that PIR-B, not
PIR-A, is the receptor expressed in the prethymic stage of
T-lineage cells. We then examined the hypothesis that PIR-
B is not only a regulator of early T cell development but
is also detrimental if expressed on mature T cells [22].
Unexpectedly, analysis of the possible inﬂuence of PIR-B
revealed no abnormalities in the development of immature
and mature T cells when PIR-B was expressed ectopically
at intrathymic stages or on peripheral T cells. Also, genetic
depletion of PIR-B did not cause any obvious alterations
in prethymic T progenitors. Interestingly, upon antigenic
or allogeneic stimulation, however, peripheral T cells with
ectopic PIR-B showed a reduced Th1 response, due to
suppression of proximal TCR signaling by constitutive cis
binding of PIR-B to MHCI on the same cell surface. These
results suggest that T cell expression of PIR-B is strictly
prohibited at the periphery so as to secure prompt immune
responses in urgent situations such as infections by fast-
multiplying bacteria. Although it remains to be determined
why prethymic early T/NK/DC progenitors express PIR-B, it
is possible that mature T cells select a transient inhibitory
system like CTLA-4, whose expression is induced upon
activation, instead of a constitutive inhibitory system such as
PIR-B.
3.2.3. Bacterial Infection. The inﬂuence of PIR-B deﬁciency
was examined in infections with bacteria such as Staphylo-
coccus aureus and Salmonella enterica [18, 19]. Pirb
−/− mice
were more susceptible to Salmonella infectionthanwild-type
C57BL/6 mice [18]. The susceptibility was in part due to the
fact that Pirb
−/− macrophages failed to control intracellular
replication of Salmonella in vitro, possibly due to imbalance
betweenPIR-AandPIR-Bintheprotectiveimmuneresponse
to bacteria [18]. Nakayama et al. [19] found that PIR-
B, and human LILRB1 and LILRB3 act as cell surface
receptors for S. aureus and Escherichia coli among various
pattern recognition receptors including Toll-like receptors
(TLRs), scavenger receptors, and lectins expressed on the
innate immune cell surface. In mouse bone marrow-derived
macrophages, PIR-B masking by mAb or genetic deletion
of PIR-B caused an enhanced TLR-mediated inﬂammatory
response to bacteria [19]. It remains unclear whether such
inhibition of TLR signaling by PIR-B is beneﬁcial or harmful
as to innate and adaptive responses to bacterial infections
in vivo. Nonetheless, the observations in this study suggest
that PIR-B plays multifaceted roles by recognizing multiple
ligands, including bacterial cell surface component(s) in
addition to MHCI and neuronal ligands. In line with these
observations, Munitz et al. [34] found very recently that PIR-
B has an inhibitory role in macrophage activation during
intestinal inﬂammatory responses, such as dextran sodium
sulfate-induced colitis, and in response to E. coli.
4. TLR9 Regulation inB-1 Cells
andAutoimmunity
4.1. B-1 Cells and Natural Antibodies. Setting aside the
reason for their expression, many inhibitory receptors are
preferentially expressed on B cells. These include the IgG Fc
receptor FcγRIIB [35, 36], a carbohydrate receptor, CD22
[37, 38], the CD100 receptor CD72 [39], a sialoglycoprotein
receptor, Siglec-G [40], a carbohydrate receptor, CD45 [41],
and the MHCI receptor PIR-B. CD45 is a phosphatase itself,
and all other receptors described above recruit SH2 domain-
containing tyrosine phosphatase (SHP)-1 and/or SHP-2, or
inositol phosphatase (SHIP) upon stimulation [40].
In mice, there are four subsets of B cells. Two sub-
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conventional B cells (B220+CD23highCD21low) and marginal
zone (MZ) B cells (B220+CD23lowCD21high) are located
primarily in secondary lymphoid organs such as the spleen
[42]. Follicular B cells participate in the responses to T
cell-dependent antigens and in the production of high-
aﬃnity IgG antibodies, while MZB cells participate in
the response to blood-borne bacterial antigens. On the
other hand, two other subsets of mature naive B cell
populations reside mainly in the peritoneal and pleural
cavities. These include B-1a (B220lowIgMhighCD11b+CD5+)
and B-1b (B220lowIgMhighCD11b+CD5−) cells. Therefore,
conventional B cells are often called B-2 cells. Although
the precise roles of these B-1 cell populations are still not
well understood, B-1b cells are mostly responsible for the
adaptive immune responses to T-independent antigens and
exert a memory function, while B-1a cells spontaneously
produce natural IgM antibodies with broad speciﬁcities,
thereby contributing to innate immunity [43, 44].
It has been suggested that innate B cells, including
MZ B, B-1a, and B-1b ones, can be potentially harmful
for maintaining peripheral tolerance, because B-1a cells,
in particular, continuously produce large amounts of IgM
natural antibodies weakly reactive to autologous tissues, but
this remains controversial. The natural IgM antibodies can
be switched to IgG, without BCR stimulation in response
to pathogen-associated molecular patterns (PAMPs) such as
bacterial cell wall components, and hypomethylated CpG
motif-containing DNA of bacterial and viral origin [42, 45].
Some PAMPs are recognized by TLRs expressed on the
cell surface or in endosomal compartments. Murine B cells
of all subsets express several TLRs [42]. Therefore, excess
stimulation of the TLR pathway in B cells such as in B-
1a ones is supposed to be connected with provocation of
autoimmunity. In fact, B-1 cells express a set of TLRs,
including TLR4, TLR7, and TLR9 [42, 46]. Several lines of
evidence indicate the importance of the regulation of TLR
signaling in B-1 cells, which prevents over-stimulation of
TLRssoasnottoevokeoverproductionofnaturalantibodies
including potentially harmful autoantibodies [46, 47]. Such
regulatory mechanisms for TLRs in B-1 cells may include
inhibitoryreceptors,andwespeculatedthatPIR-Bcouldplay
ar o l eh e r e .
Interestingly, in Pirb
−/− mice the peritoneal B-1a cell
population signiﬁcantly increases, particularly with aging,
compared to in wild-type C57BL/6 mice [10]. However, it
has not been determined how the B-1a cell compartment is
regulated by PIR-B or what the physiological or pathological
consequence of the expanded B-1a cells is in the contexts
of infection and autoimmunity. We found that PIR-B on
B-1 cells suppresses TLR9 signaling via Bruton’s tyrosine
kinase (Btk) dephosphorylation, which leads to attenuated
activation of NF-κB p65RelA and blocks the production of
natural IgM antibodies, including anti-IgG Fc autoantibod-
ies or rheumatoid factor (RF) in particular [11].
4.2. Autoimmune Glomerulonephritis. Initially we observed
that Pirb
−/− mice were grossly normal and survived well,
at least to 50 weeks of age, without any abnormalities in
the histology of their tissues including glomeruli. However,
Pirb
−/− mice with the lpr mutation of Fas (Pirb
−/−Faslpr
mice) were markedly short lived, because of a deﬁcit in
renalfunctionduetothedevelopmentofglomerulonephritis
with the depositing of IgG, IgM, and C3. While the levels
of IgM- and IgG-RF were high in Faslpr mice, these levels
were further elevated in Pirb
−/−Faslpr animals. On the
other hand, the serum levels of anti-dsDNA and -ssDNA
autoantibodies were also high in Faslpr mice, but they were
not elevated further in Pirb
−/−Faslpr mice, indicating that
PIR-B deﬁciency has a marked impact on the augmentation
ofRFproductioninvivo.TheperitonealB-1acellandsplenic
plasma cell populations were also increased in Pirb
−/−Faslpr
mice.Fromthesedata,itwasconcludedthatPIR-Bdeﬁciency
in combination with Faslpr renders mice susceptible to the
development of autoimmune glomerulonephritis, which is
accompanied by signiﬁcantly elevated RF production with
robust production of other autoantibodies including those
against self DNA.
4.3. TLR9 Signal in B-1 Cells. RF is one of the autoreactive
natural antibodies reacting with the Fc portion of IgG,
whose primary role is believed to be as the ﬁrst line
defense against infections. It is also a marker of rheumatoid
arthritisandotherconnectivetissuediseasessuchassystemic
lupus erythematosus and infectious diseases. However, the
pathogenicity of RF in autoimmune diseases has not been
established suﬃciently. Like other natural autoreactive anti-
bodies such as those reactive with phosphatidylcholine, the
main source of RF is considered to be B-1 cells [48]. To
determine the precise source, the RF levels in sera from B6
and Pirb
−/− mice were examined in the absence of Faslpr,
which might have a great inﬂuence on the RF level.
Given the augmented RF production and enlarged B-
1a cell population in Pirb
−/−Faslpr mice, our attention next
turned to the characteristics of Pirb
−/− B-1 cells. Pirb
−/− B-
1 cells proliferated particularly well upon stimulation with
CpG (TLR9 ligand) compared to wild-type ones, indicating
an important role of TLR9 in B-1 cell activation and its
regulation by PIR-B. Total IgM, IgM-RF, and IL-10 release
was also more elevated in Pirb
−/− B-1 cells than in wild-type
ones. While B-1a and B-1b cells express PIR-B molecules
more abundantly on their surface than B-2 cells [25], the
expression of PIR-A, an activating counterpart of PIR-B,
was not detected on B-1a cells [11], suggesting the presence
of a PIR-B-mediated inhibitory signaling that speciﬁcally
regulates TLR9.
Like in mast cells and splenic B cells stimulated by IgE
receptor or BCR crosslinking, respectively, CpG induced
augmented PIR-B phosphorylation in B-1 cells, which was
accompanied by an increase in SHP-1 recruitment, whereas
such events were not observed in TLR9-deﬁcient cells, which
led the conclusion that CpG-mediated PIR-B phosphory-
lation occurs downstream of TLR9 [11]. Preceding studies
indicated that, in splenic B cells, Lyn is the major Src
family kinase that phosphorylates PIR-B [49]. However,
it is not known whether or not this is also the case in
peritoneal B-1 cells. The phosphorylation level of Lyn was6 Journal of Biomedicine and Biotechnology
indeed augmented as early as 5 min after CpG stimulation
of B-1 cells regardless of the presence or absence of PIR-
B. However, augmented phosphorylation of Lyn was not
observed in TLR9-deﬁcient B-1 cells. Also, Lyn and PIR-
B were co-immunoprecipitated from a macrophage lysate
after stimulation with CpG. These results indicate that Lyn is
rapidly activated downstream of TLR9 and strongly suggest
that Lyn is a candidate, if not the sole, Src family kinase that
phosphorylates PIR-B.
What are the downstream signal cascades, such as the
NF-κB and MAP kinase pathways, of TLR9 modulated
by PIR-B in B-1 cells? MAPK and Erk were signiﬁcantly
augmented after CpG stimulation, but their levels and
kinetics were comparable in normal and Pirb
−/− B-1 cells.
On the other hand, p65 NF-κB phosphorylation was found
to be markedly augmented in Pirb
−/− B-1 cells after CpG
stimulation, indicating that the NF-κB pathway could be the
target step located most downstream of regulation through
Lyn-mediated PIR-B phosphorylation (Figure 1).
Then, which molecule mediates the PIR-B-SHP-1-
initiated inhibitory signaling pathway to the TLR9-NF-κB
cascade? In a B cell line, IIA1.6 cells, Syk and Btk were found
to be the substrates for SHP-1 recruited to PIR-B ITIMs
upon stimulation of BCR [50]. Examination of the possible
involvement of these two molecules in the TLR9 pathway
revealed that the phosphorylation status of Syk upon CpG
addition to B-1 cells did not show enhancement of the
phosphorylation, while Btk phosphorylation was markedly
augmentedafterCpGadditioninbothwild-typeandPirb
−/−
B-1 cells, and the augmentation was higher in Pirb
−/− B-
1 cells, indicating that Btk is a major substrate for SHP-1
(Figure 1). These results indicate that Btk phosphorylation
is dependent, at least partly, on a Src family kinase, most
likely Lyn, and that NF-κB p65RelA phosphorylation is also a
criticaleventdownstreamofSrcfamilykinaseactivation.The
molecular mechanism for the TLR9-initiated Lyn activation
iscurrentlynotknown.AlthoughSHP-1isacriticalregulator
of type I interferon production by macrophages and DCs
throughinhibitionofIRAK1activationdownstreamofTLR4
[51],augmentedIRAK1activationwasnotobservedinCpG-
B stimulated Pirb
−/− B-1 cells [11], suggesting that B-1 cells
preferentiallyutilizeBtkasakeyintersectingmoleculeforthe
inhibitory circuit (Figure 1).
Recent studies have shown that Btk is an important
mediator of the TLR9 cascade in addition to MyD88 and
TRAF [52, 53] .B t ki sr e q u i r e df o rN F - κB activation, partic-
ipating in the pathway leading to increased phosphorylation
of p65RelA activated by TLR8 and TLR9 [53, 54]. As is well
known, Btk is a critical kinase for the development and func-
tion of B cells including B-1 cells by ensuring BCR signaling,
ashasbeendemonstratedinimmunocompromisedXid mice
and human X-linked agammaglobulinemia, in which Btk
is dysfunctional [55, 56]. Btk deletion in mice induced
defective development of B cells including B-1 ones and their
function [57]. The ﬁnding that Btk is a critical link between
the TLR9 cascade and the PIR-B-mediated regulatory loop,
particularly in B-1 cells expressing abundant PIR-B [11],
provides an insight into the mechanism underlying the
crosstalk between the innate immune system and ITIM-
harboring receptors.
4.4. Autoimmunity and PIR-B: Questions Remaining. How
are the observations on TLR9 signaling in B-1 cells relevant
to the prevention of autoimmunity? In this context, several
feedback regulators for TLR9 activation have been identiﬁed.
These include SOCS1 [58], ATF3 [59], IRF-4 [60], and SHP-
1[ 51]. For example, SOCS1-mediated feedback regulation
seems to occur after several hours of TLR9 activation
followed by inﬂammatory cytokine induction [58]. It is
very characteristic that the PIR-B-mediated suppression of
the TLR9 cascade takes place at several minutes after CpG
addition to B-1 cells. Therefore, PIR-B in the TLR9 of B-1
cells does not seem to be a feedback regulatory element but
an immediate-early regulator just like the one in mast cell
regulation after IgE receptor crosslinking [14, 61] and in B-2
cells upon BCR stimulation [10, 62, 63].
Can RF produced by B-1 cells trigger or exacerbate
glomerulonephritis in Pirb
−/−Faslpr mice? CD5+ B-1 cells or
B-1acellsareconsideredtobeinvolvedinsomeautoimmune
diseases in which RF is frequently detected or RF production
is directly coupled to the disease [64–66]. Also, RF+ Bc e l l s
are eﬀectively activated via the IgG2a-chromatin immune
complex and synergistic stimulation of TLR9-mediated
signaling [67]. It is additionally known that RF can bind
to anti-dsDNA autoantibodies and form immune complexes
[68]. Also, it has been reported that RF itself exhibits cryo-
globulin activity and causes glomerulonephritis without any
other additional factors [69]. Therefore, glomerulonephritis
in Pirb
−/−Faslpr mice exhibiting markedly and speciﬁcally
elevated IgM- and IgG-RF production suggests that these
anti-IgG Fc autoantibodies worsen the disease, presumably
by accelerating the deposition of IgG autoantibodies against
glomerular basement membranes.
Do other TLRs, such as TLR4 and TLR7, in B-1 and
B-2 cells possess a similar regulatory system involving PIR-
B to that of TLR9? In this regard, it is of note that TLR4-
mediated cytokine production by mast cells is also negatively
regulated by PIR-B [14], although the mechanism has yet to
be elucidated. Therefore, it is likely that some TLR-mediated
activation cascades in B cells could be linked to the PIR-B-
SHP-1-mediatedsuppressioninadditiontothecaseofTLR9.
On the other hand, TLR4 response in macrophages was not
aﬀected by PIR-B [19, 34]. The reason why TLR4-induced
responses are regulated diﬀerentially in the diﬀerential cell
populations is not known currently. However, one may
speculate that diﬀerent cells may be diﬀerently dependent
on any TLR4-initiated, PIR-B-mediated regulatory pathway
such as the Lyn-PIR-B-SHP-1-Btk axis identiﬁed in B-1 cells
[11]. Such regulation of an innate immune response via
TLRs by constitutive and activation-dependent immediate-
earlysuppressionofPIR-Bcouldbepromisingforpreventing
autoimmunity.
5. Concluding Remarks
In recent studies on Pirb
−/− mice, there were two impor-
tant observations. Firstly, the TLR9 system in B-1 cells isJournal of Biomedicine and Biotechnology 7
regulated by PIR-B via the Btk intersection, at which PIR-
B phosphorylation is immediately augmented by TLR9-
initiated Lyn activation, and the concomitant enhancement
of SHP-1 recruitment to augmented phospho-ITIMs of PIR-
B leads to Btk dephosphorylation, which then attenuates
the phosphorylation level of NF-κB p65RelA. Secondly,
excessive production of RF together with other autoanti-
bodies by B-1 cells can be linked to glomerulonephritis
with IgG immune complex deposition. Considering these
observations, it is becoming increasingly important for
manipulation of the PIR-B-mediated inhibitory system in
the regulation of autoimmune disease while maintaining
the integrity of TLR9-mediated microbial sensing, in such
cases as rheumatoid arthritis. Understanding of the PIR-B
system in B-1 cells may lead to the development of novel and
eﬀective ways of controlling autoimmune diseases.
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